Search
Search Results
-
BRAF/MEK-targeted therapy in BRAF ex15 p.T599dup mutation-driven NSCLC: a case report
BRAF mutations are found in 1–5% of non-small-cell lung cancer (NSCLC), with V600 and non-V600 accounting for approximately 50% each. It has been...
-
BRAF inhibitors in BRAF V600E-mutated ameloblastoma: systematic review of rare cases in the literature
BackgroundAmeloblastoma in 66% of the cases harbor a somatic mutation of the “mitogen-activated protein kinase” signaling pathway (BRAF V600E). In...
-
Histological transformation to gliosarcoma with combined BRAF/MEK inhibition in BRAF V600E mutated glioblastoma
The identification of BRAF V600 mutation in multiple cancers beyond melanoma and the development of combined BRAF and MEK targeting agents have...
-
BRAF — a tumour-agnostic drug target with lineage-specific dependencies
In June 2022, the FDA granted Accelerated Approval to the BRAF inhibitor dabrafenib in combination with the MEK inhibitor trametinib for the...
-
Therapeutic Strategies in BRAF V600 Wild-Type Cutaneous Melanoma
There have been many recent advances in melanoma therapy. While 50% of melanomas have a BRAF mutation and are a target for BRAF inhibitors, the...
-
BRAFV600E-mutant metastatic NSCLC: disease overview and treatment landscape
In this review, we cover the current understanding of BRAF mutations and associated clinical characteristics in patients with metastatic NSCLC,...
-
A phase I/II study of MCS110 with BRAF/MEK inhibition in patients with melanoma after progression on BRAF/MEK inhibition
Background: Prognosis for patients with metastatic melanoma has been improved dramatically with the development of BRAF/MEK directed therapy and...
-
Toxicities from BRAF and MEK Inhibitors: Strategies to Maximize Therapeutic Success
Purpose of ReviewThis report highlights several of the recent therapeutic advancements in the treatment of BRAF -mutant tumors, discusses the most...
-
Oncogenic BRAF noncanonically promotes tumor metastasis by mediating VASP phosphorylation and filopodia formation
BRAF is frequently mutated in various cancer types and contributes to tumorigenesis and metastasis. As an important switch in RAS signaling pathway,...
-
Fertilität, Teratogenität und Kontrazeption bei BRAF-/MEK-Inhibition
BackgroundTargeted mutation-based therapy with BRAF and MEK inhibitors has become an integral part of systemic therapy for metastatic melanoma in the...
-
Paediatric pancreatic acinar cell carcinoma with a novel SEC31A-BRAF fusion gene
Paediatric pancreatic acinar cell carcinoma (PACC) presents a diagnostic challenge, often confused with pancreatoblastoma (PB) due to its rarity. It...
-
Integrated molecular and clinical analysis of BRAF-mutant glioma in adults
BRAF mutations are a significant driver of disease in pediatric low-grade glioma, but the implications of BRAF alterations on the clinical course and...
-
Targeted therapy in BRAF mutated aggressive papillary craniopharyngioma: a case report and overview of the literature
BackgroundPapillary craniopharyngiomas harbor the BRAF V600E mutation, which paves the way for using BRAF inhibitor molecules to treat tumors...
-
Targeting DUSP5 suppresses malignant phenotypes of BRAF-mutant thyroid cancer cells and improves their response to sorafenib
PurposeThe role of dual-specificity phosphatase-5 (DUSP5) in BRAF-mutant thyroid cancers remains unclear. The aims of this study are to investigate...
-
BRAF V600E Mutation Lacks Association with Poorer Clinical Prognosis in Papillary Thyroid Carcinoma
BackgroundPrevious literatures showed wide range of prevalence of BRAF V600E in papillary thyroid carcinoma (PTC). The correlation of BRAF V600E ...
-
Systematic review and cumulative analysis of clinical properties of BRAF V600E mutations in PLNTY histological samples
PurposePolymorphous low-grade neuroepithelial tumors of the young (PLNTY) represent a rare pediatric-type tumor that most commonly presents as...
-
Targeted therapy with vemurafenib in BRAF(V600E)-mutated anaplastic thyroid cancer
BackgroundAnaplastic thyroid cancer (ATC) is one of the most aggressive malignancies, representing less than 5% of all thyroid carcinomas. Τhe median...
-
Preliminary exploration of the effects of environmental factors on the microsatellite status of BRAF-mutated colorectal cancer
BackgroundTo investigate the expression of EBV products and frequency of gallstone disease (GD) among different microsatellite status in colorectal...
-
A computational approach to assessing the prognostic implications of BRAF and RAS mutations in patients with papillary thyroid carcinoma
Papillary thyroid carcinoma (PTC) is the most common thyroid cancer, posing a growing clinical challenge. PTC exhibits two age-related peaks, with...
-
Early molecular diagnosis of BRAF status drives the neurosurgical management in BRAF V600E-mutant pediatric low-grade gliomas: a case report
BackgroundTo date, this is the only report showing with close and consecutive magnetic resonance images the extremely rapid response of two types of...
